2015 June - 26 articles
Background: The endpoints of progression-free survival (pfs) and time-to-progression (ttp) are frequently used to evaluate the clinical benefit of anticancer drugs. However, the surrogacy of those endpoints for overall survival (os) is not validated...
Current Oncology has made great strides over the years to improve the quality, success, and sustainability of our renowned journal. [...]
About the ongoing breast cancer screening mammography debate (less a controversy, because many points of consensus and convergence are present if not always apparent), we can make these points as prelude: that it is complex; that it is naïvely implau...
BACKGROUND [...]
In the Canadian National Breast Screening Study, the hazard ratio for breast cancer–specific death was 1.47 for women with cancers detected in the prevalence screening round, 0.9 for women with cancers detected in the subsequent four screening rounds...
There is a clear evidence-to-practice gap in bladder cancer care. [...]
Physicians receive many online survey requests from both academic and pharmaceutical sources [...]
Introduction: Randomized controlled trials (RCTS) are the “gold standard” for establishing treatment efficacy; however, efficacy does not automatically translate to a comparable level of effectiveness in routine practice. Our objectives were to (1) d...
Background: Proliferative scoring of breast tumours can guide treatment recommendations, particularly for estrogen receptor (ER)–positive, HER2-negative, T1–2, N0 disease. Our objectives were to (1) estimate the proportion of such patients for whom p...
Introduction: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (RDF) in the prophylaxis of radiation-induced nausea and vomiting (RINV). Rapidly dissolving film formulations facilitate drug de...
Background: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cance...
After some decades of contention, one can almost despair and conclude that (paraphrasing) “the mammography debate you will have with you always.” Against that sentiment, in this review I argue, after reflecting on some of the major themes of this lon...
Cancer is the one of the major causes of death worldwide. More than 16 million new cancer cases are expected by 2020, and it is estimated that cancer will then be the cause of more than 10 million deaths per year[...]
In December 2014, on the force Web site, executive director Sue Friedman, heralded a game-changing holiday gift for people with BRCA mutations: “Today is a landmark for the hboc [hereditary breast and ovarian cancer] community” [...]
Purpose: We assessed the quality of life (qol) of nasopharyngeal carcinoma (npc) survivors with a survival time of more than 2 years in Fujian, China, and we analyzed factors influencing qol. Method: We calculated the prevalence of psychological dist...
Background Treatment for advanced non-small-cell lung cancer (NSCLC), especially in patients with wild-type EGFR, remains limited. Recently, erlotinib, a tyrosine kinase inhibitor (TKI) targeting EGFR mutation, was approved as second-line treatment i...
Background: The importance of histologic classification in selecting the appropriate systemic therapy for non-small-cell lung cancer (NSCLC) came to attention in 2007. In British Columbia, that information was communicated through international and n...
Background: For cancer patients, information about their disease and its treatment is often delivered within a short time period, potentially leading to patient misunderstanding, which can impede optimal patient care. In this 3-part clinical study, w...
Background: Delineating the nodal clinical target volume (CTVn) remains a challenging task in patients with cervical or upper thoracic esophageal carcinoma (EC). In particular, the extent of the lymph area that should be included in the irradiation f...
Introduction: This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients—unselected, selected, and molecularly selected—in three treatmen...
Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of mult...
The guideline article “Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations” in this journal for the management of hypersensitivity reactions (HSR) to this group of chemotherapy agents is...
Dr. Pierre Band’s book on The History of Medical Oncology from Early Days does matter—particularly nowadays, in the era of fast developments and a rising number of subspecialties with language at times too specialized to follow. From that perspective...
Therapeutic Revolution: The History of Medical Oncology From Early Days to the Creation of the Subspecialty is a book about the history of medical oncology, the extraordinary turbulence that permeated the early years of the field, and the events that...
[I]f you didn’t know history, you didn’t know anything [...]
His face looked sore, and there was a gaping hole in his left cheek that bore down to the upper set of his dentition [...]
